Bacillus Coagulans: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Bacillus coagulans (B. coagulans) is a type of probiotic ("good" bacteria). It isn't naturally found in the body, but it produces lactic acid in the gut.

B. coagulans is now known as Weizmannia coagulans. However, most products continue to use the name Bacillus. Also, some products containing B. coagulans are marketed as Lactobacillus sporogenes. Although both lactobacillus and B. coagulans produce a compound called lactic acid, unlike lactobacillus, B. coagulans forms spores. Spores are important for telling B. coagulans apart from other lactic acid bacteria.

People take B. coagulans for constipation and irritable bowel syndrome (IBS). It is also used for diarrhea, gas, indigestion, and many other conditions, but there is no good scientific evidence to support these other uses.

Don't confuse B. coagulans with other probiotics, or with fermented food products such as fermented milk, kefir, or yogurt. These are not the same.

Uses & Effectiveness

Possibly Effective for

Constipation. Taking B. coagulans by mouth seems to help relieve constipation.
A long-term disorder of the large intestines that causes stomach pain (irritable bowel syndrome or IBS). Taking B. coagulans by mouth seems to help relieve symptoms of IBS.

There is interest in using B. coagulans for a number of other purposes, but there isn't enough reliable information to say whether it might be helpful.

Side Effects

When taken by mouth: B. coagulans is possibly safe. It's been used safely in doses of up to 6 billion colony-forming units (CFUs) daily for up to 3 months. Lower doses have been used safely for up to 1 year.

Special Precautions and Warnings

Pregnancy and breast-feeding: There isn't enough reliable information to know if B. coagulans is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.

Children: B. coagulans is possibly safe when taken by mouth by most infants and children. It's been used safely in infants in doses of up to 100 million CFUs daily for up to one year. However, there isn't enough reliable information to know if Bacillus coagulans is safe for very small premature infants.

Interactions

Minor Interaction

Be watchful with this combination

Antibiotic drugs interacts with Bacillus Coagulans
B. coagulans is a type of friendly bacteria. Antibiotics are used to reduce harmful bacteria in the body. Taking antibiotics along with B. coagulans can reduce the effects of B. coagulans. To avoid this interaction, take B. coagulans products at least 2 hours before or after antibiotics.

Dosing

B. coagulans has most often been used by adults in doses of 1-2 billion colony-forming units (CFUs) by mouth daily for 4-12 weeks. Speak with a healthcare provider to find out what dose might be best for a specific condition.

View References

REFERENCES:

Saxelin M, Chuang NH, Chassy B, et al. Lactobacilli and bacteremia in southern Finland 1989-1992. Clin Infect Dis 1996;22:564-6.

Tynkkynen S, Singh KV, Varmanen P. Vancomycin resistance factor of Lactobacillus rhamnosus GG in relation to enterococcal vancomycin resistance (van) genes. Int J Food Microbiol 1998;41:195-204.

Klein G, Zill E, Schindler R, et al. Peritonitis associated with vancomycin-resistant Lactobacillus rhamnosus in a continuous ambulatory peritoneal dialysis patient; organism identification, antibiotic therapy, and case report. J Clin Microbiol 1998;36:1781-3.

Kalima P, Masterton RG, Roddie PH, et al. Lactobacillus rhamnosus infection in a child following bone marrow transplant. J Infect 1996;32:165-7.

Goldin BR. Health Benefits of probiotics. Br J Nutr 1998;80:S203-7.

Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999;28:1159-60.

Reid G, Bruce AW, Cook RL, et al. Effect on urogenital flora of antibiotic therapy for urinary tract infection. Scand J Infect Dis 1990;22:43-7.

McGroarty JA. Probiotic use of lactobacilli in the human female urogenital tract. FEMS Immunol Med Microbiol 1993;6:251-64.

Velraeds MM, van der Mei HC, Reid G, Busscher HJ. Inhibition of initial adhesion of uropathogenic Enterococcus faecalis by biosurfactants from Lactobacillus isolates. Appl Environ Microbiol 1996;62:1958-63.

MacGregor G, Smith AJ, Thakker B, Kinsella J. Yoghurt biotherapy: contraindicated in immunosuppressed patients? Postgrad Med J 2002;78:366-7.

Land MH, Rouster-Stevens K, Woods CR, et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005;115:178-81.

De Groote MA, Frank DN, Dowell E, et al. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 2005;24:278-80.

Duc LH, Hong HA, Barbosa TM, et al. Characterization of Bacillus probiotics available for human use. Appl Environ Microbiol 2004;70:2161-71.

Probiotics for antibiotic-associated diarrhea. Pharmacist's Letter / Prescriber's Letter 2000;16(1):160103.

Hyronimus B, Le Marrec C, Urdaci MC. Coagulin, a bacteriocin-like inhibitory subtances produced by Bacillus coagulans I4. J Appl Microbiol 1998;85:42-50.

Donskey CJ, Hoyen CK, Das SM, et al. Effect of oral Bacillus coagulans administration on the density of vancomycin-resistant enterococci in the stool of colonized mice. Lett Appl Microbiol 2001;33:84-8.

Czaczyk K, Tojanowska K, Mueller A. Antifungal activity of Bacillus coagulans against Fusarium sp. Acta Microbiol Pol 2002;51:275-83.

Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol. 2013;47(5):437-9.

Khalighi AR, Khalighi MR, Behdani R, et al. Evaluating the efficacy of probiotic on treatment in patients with small intestinal bacterial overgrowth (SIBO)--a pilot study. Indian J Med Res. 2014 N ov;140(5):604-8.

Urgesi R, Casale C, Pistelli R, et al. A randomized double-blind placebo-controlled trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox) in patients with irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2014;18(9):1344-53.

Jurenka JS. Bacillus coagulans: Monograph. Altern Med Rev 2012;17(1):76-81.

De Vecchi E, Drago L. Lactobacillus sporogenes or Bacillus coagulans: misidentification or mislabeling? Int J Probiotics Prebiotics 2006;1(1):3-10.

Chandra RK. Effect of Lactobacillus on the incidence and severity of acute rotavirus diarrhea in infants. A prospective placebo-controlled double-blind study. Nutr Res 2002;22:65-9.

Majeed M, Nagabhushanam K, Natarajan S, et al. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant irritable bowel syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J 2016;15:21.

Pande C, Kumar A, Sarin SK. Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized-controlled trial. Eur J Gastroenterol Hepatol 2012;24(7):831-9.

Riazi S, Wirawan RE, Badmaev V, Chikindas ML. Characterization of lactosporin, a novel antimicrobial protein produced by Bacillus coagulans ATCC 7050. J Appl Microbiol 2009;106(4):1370-7.

Sari FN, Dizdar EA, Oguz S, et al. Oral probiotics: Lactobacillus sporogenes for prevention of necrotizing enterocolitis in very low-birth weight infants: a randomized, controlled trial. Eur J Clin Nutr 2011;65(4):434-9.

Mandel DR, Eichas K, Holmes J. Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med 2010;10:1.

Dolin BJ. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol 2009;31(10):655-9.

Kalman DS, Schwartz HI, Alvarez P, et al. A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms. BMC Gastroenterol 2009;9:85.

Dutta P, Mitra U, Dutta S, et al. Randomised controlled clinical trial of Lactobacillus sporogenes (Bacillus coagulans), used as a probiotic in clinical practice, on acute watery diarrhea in children. Trop Med Int Health 2011;16(5):555-61.

Yang OO, Kelesidis T, Cordova R, Khanlou H. Immunomodulation of antiretroviral drug-suppressed chronic HIV-1 infection in an oral probiotic double-blind placebo-controlled trial. AIDS Res Hum Retroviruses 2014;30(10):988-95.

Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med 2009;121(2):119-24.

Maity C, Gupta AK. A prospective, interventional, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Bacillus coagulans LBSC in the treatment of acute diarrhea with abdominal discomfort. Eur J Clin Pharmacol. 2019;75(1):21-31.

Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.

Sendil S, Shrimanker I, Mansoora Q, Goldman J, Nookala VK. Lactobacillus rhamnosus bacteremia in an immunocompromised renal transplant patient. Cureus. 2020;12(2):e6887.

Abhari K, Saadati S, Yari Z, et al. The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial. Clin Nutr ESPEN. 2020;39:53-60.

Soman RJ, Swamy MV. A prospective, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of SNZ TriBac, a three-strain Bacillus probiotic blend for undiagnosed gastrointestinal discomfort. Int J Colorectal Dis. 2019;34(11):1971-1978.

Chang CW, Chen MJ, Shih SC, et al. Bacillus coagulans (PROBACI) in treating constipation-dominant functional bowel disorders. Medicine (Baltimore). 2020;99(19):e20098.

Kumar VV, Sudha KM, Bennur S, Dhanasekar KR. A prospective, randomized, open-label, placebo-controlled comparative study of Bacillus coagulans GBI-30,6086 with digestive enzymes in improving indigestion in geriatric population. J Family Med Prim Care. 2020;9(2):1108-1112.

Albarillo FS, Shah U, Joyce C, Slade D. Lactobacillus rhamnosus Infection: A single-center 4-year descriptive analysis. J Glob Infect Dis. 2020;12(3):119-123.

Pasala S, Singer L, Arshad T, Roach K. Lactobacillus endocarditis in a healthy patient with probiotic use. IDCases. 2020;22:e00915.

Agrawal S, Tuchman ES, Bruce MJ, Theodorou ME. Fatal Lactobacillus endocarditis in a patient with transcatheter aortic valve replacement. BMJ Case Rep. 2020;13(11):e236835.

Antoun M, Hattab Y, Akhrass FA, Hamilton LD. Uncommon pathogen, Lactobacillus, causing infective endocarditis: Case report and review. Case Rep Infect Dis. 2020;2020:8833948.

Zhang J, Guo J, Li D, et al. The efficacy and safety of Clostridium butyricum and Bacillus coagulans in Helicobacter pylori eradication treatment: An open-label, single-arm pilot study. Medicine (Baltimore). 2020;99(45):e22976.

Gupta AK, Maity C. Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study. Medicine (Baltimore). 2021;100(3):e23641.

Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178.

Franko B, Vaillant M, Recule C, Vautrin E, et al. Lactobacillus paracasei endocarditis in a consumer of probiotics. Med Mal Infect. 2013;43(4):171-3.

Campbell RE, Miller A, Afroze A. Native valve endocarditis secondary to Lactobacillus paracasei bacteremia. Consultant. 2020;60(9):27-8.

Kato K, Funabashi N, Takaoka H, et al. Lactobacillus paracasei endocarditis in a consumer of probiotics with advanced and severe bicuspid aortic valve stenosis complicated with diffuse left ventricular mid-layer fibrosis. Int J Cardiol. 2016;224:157-161.

McFarland LV, Karakan T, Karatas A. Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. EClinicalMedicine. 2021;41:101154.

Hoffman JR, Hoffman MW, Zelicha H, ET AL. The Effect of 2 Weeks of Inactivated Probiotic Bacillus coagulans on endocrine, inflammatory, and performance responses during self-defense training in soldiers. J Strength Cond Res. 2019;33(9):2330-2337.

Wauters L, Slaets H, De Paepe K, et al. Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2021;6(10):784-792.

Madempudi RS, Neelamraju J, Ahire JJ, Gupta SK, Shukla VK. Bacillus coagulans Unique IS2 in constipation: A double-blind, placebo-controlled study. Probiotics Antimicrob Proteins. 2020;12(2):335-342.

Kang S, Park MY, Brooks I, et al. Spore-forming Bacillus coagulans SNZ 1969 improved intestinal motility and constipation perception mediated by microbial alterations in healthy adults with mild intermittent constipation: A randomized controlled trial. Food Res Int 2021;146:110428.

Venkataraman R, Shenoy R, Ahire JJ, Neelamraju J, Madempudi RS. Effect of Bacillus coagulans Unique IS2 with Lactulose on Functional Constipation in Adults: a Double-Blind Placebo Controlled Study. Probiotics Antimicrob Proteins 2021.

Anaya-Loyola MA, Enciso-Moreno JA, López-Ramos JE, et al. Bacillus coagulans GBI-30, 6068 decreases upper respiratory and gastrointestinal tract symptoms in healthy Mexican scholar-aged children by modulating immune-related proteins. Food Res Int. 2019;125:108567.

Velayati A, Kareem I, Sedaghat M, et al. Does symbiotic supplementation which contains Bacillus Coagulans Lactobacillus rhamnosus, Lactobacillus acidophilus and fructooligosaccharide has favourite effects in patients with type-2 diabetes? A randomised, double-blind, placebo-controlled trial. Arch Physiol Biochem. 2021 Jun 2:1-8.

Zhang T, Zhang C, Zhang J, Sun F, Duan L. Efficacy of probiotics for irritable bowel syndrome: A systematic review and network meta-analysis. Front Cell Infect Microbiol 2022;12:859967.

Tarik M, Ramakrishnan L, Bhatia N, et al. The effect of Bacillus coagulans Unique IS-2 supplementation on plasma amino acid levels and muscle strength in resistance trained males consuming whey protein: a double-blind, placebo-controlled study. Eur J Nutr 2022;61(5):2673-2685.

Li Z, Guan Z, Bai N, et al. Bacillus coagulans TBC169 probiotics for the recovery of intestinal function after gynecological laparoscopic surgery: a randomized, placebo-controlled trial. Int J Clin Pharm 2022;44(6):1287-1295.

Gupta RS, Patel S, Saini N, Chen S. Robust demarcation of 17 distinct Bacillus species clades, proposed as novel Bacillaceae genera, by phylogenomics and comparative genomic analyses: description of Robertmurraya kyonggiensis sp. nov. and proposal for an emended genus Bacillus limiting it only to the members of the Subtilis and Cereus clades of species. Int J Syst Evol Microbiol. 2020;70(11):5753-5798.

Poindexter B; Committee on fetus and newborn. Use of Probiotics in Preterm Infants. Pediatrics. 2021;147(6):e2021051485.

US Food and Drug Administration (FDA). Dear Healthcare Provider Letter: Warning Regarding Use of Probiotics in Preterm Infants. September 2023. Available at: https://www.fda.gov/media/172606/download?attachment. Accessed November 1, 2023.

Pillai A, Tan J, Paquette V, Panczuk J. Does probiotic bacteremia in premature infants impact clinically relevant outcomes? A case report and updated review of literature. Clin Nutr ESPEN. 2020;39:255-259.

Dani C, Coviello C C, Corsini I I, Arena F, Antonelli A, Rossolini GM. Lactobacillus Sepsis and Probiotic Therapy in Newborns: Two New Cases and Literature Review. AJP Rep. 2016;6(1):e25-9.

Zbinden A, Zbinden R, Berger C, Arlettaz R. Case series of Bifidobacterium longum bacteremia in three preterm infants on probiotic therapy. Neonatology 2015;107(1):56-9.

Bertelli C, Pillonel T, Torregrossa A, et al. Bifidobacterium longum bacteremia in preterm infants receiving probiotics. Clin Infect Dis 2015;60(6):924-7.

Esaiassen E, Cavanagh P, Hjerde E, Simonsen GS, Støen R, Klingenberg C. Bifidobacterium longum subspecies infantis bacteremia in 3 extremely preterm infants receiving probiotics. Emerg Infect Dis 2016;22(9):1664-6.

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2025 by Therapeutic Research Center, LLC. All Rights Reserved.